BRISTOL MYERS SQUIBB

BMS-986446

This clinical trial’s goal is to determine the impact BMS-986446 on cognitive and functional decline in participants with early Alzheimer’s disease. BMS-986446 is an anti-MTBR Tau Monoclonal antibody.

Eligibility: Individuals who have mild cognitive impairment (MCI) or early Alzheimer’s disease.

Status: RECRUITING

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.